Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Candel Therapeutics, Inc.CADL · Entity 4969 | Director | September 08, 2026 | September 10, 2026 |
| LIGAND PHARMACEUTICALS INCLGND · Entity 3825 | Director | September 22, 2026 | September 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Candel Therapeutics, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.60 · Expires 2036-09-08 | Direct | 64,000 |
Reported balance
After 2026-09-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-08 · Grant · Acquired 64,000 · Balance 64,000 F1: The shares underlying this option shall vest and become exercisable in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying this option shall vest and become exercisable in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.
LIGAND PHARMACEUTICALS INC
Report date September 22, 2026 · Filed September 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,782 |
Reported balance
After 2026-09-22 transaction · row 1
1 source rowRow 1 · 2026-09-22 · Tax withholding · Disposed 115 · Balance 3,782 F1: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 22, 2026 Filed Sep 24, 2026 21:22 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 115 | $298.50 | $34,327.50 |
DisclosureSEC source: 0002001011-26-000142 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,782 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| September 10, 2026 Filed Sep 14, 2026 20:59 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | SaleCommon Stock | 1,200 | $285.00 | $342,000.00 |
DisclosureSEC source: 0002001011-26-000140 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,897 Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 20:24 UTC | Candel Therapeutics, Inc. CADL · Entity 4969 | GrantStock Option (Right to Buy) · Derivative | 64,000 | $0.00 Strike: $12.60 | $0.00 |
DisclosureSEC source: 0001193125-26-387924 · ownership.xml · derivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2036-09-08 F1 · derivative.exercise_date: The shares underlying this option shall vest and become exercisable in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 2,938 | $0.00 Strike: $237.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000101 · edgardoc.xml · derivative · entry 3 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,938 Underlying: Common Stock · 2,938 shares Expires 2036-06-05 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 182 | $237.00 | $43,134.00 |
DisclosureSEC source: 0002001011-26-000101 · edgardoc.xml · nonDerivative · entry 2 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,097 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 23:42 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 836 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-26-000101 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,279 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 5, 2026. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| September 22, 2025 Filed Sep 24, 2025 21:10 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 115 | $170.77 | $19,638.55 |
DisclosureSEC source: 0002001011-25-000081 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,443 F1 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,783 | $0.00 Strike: $105.99 | $0.00 |
DisclosureSEC source: 0002001011-25-000043 · edgardoc.xml · derivative · entry 3 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,783 Underlying: Common Stock · 5,783 shares Expires 2035-06-06 F3 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | Tax withholdingCommon Stock | 188 | $105.99 | $19,926.12 |
DisclosureSEC source: 0002001011-25-000043 · edgardoc.xml · nonDerivative · entry 2 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,558 F2 · shares: Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of restricted stock units. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 23:21 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,209 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-25-000043 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,746 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 6, 2025. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 5,444 | $0.00 Strike: $80.06 | $0.00 |
DisclosureSEC source: 0002001011-24-000060 · edgardoc.xml · derivative · entry 2 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444 Underlying: Common Stock · 5,444 shares Expires 2034-06-14 F2 · derivative.exercise_date: Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| June 14, 2024 Filed Jun 19, 2024 01:27 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 1,252 | $0.00 | $0.00 |
DisclosureSEC source: 0002001011-24-000060 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,537 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. Acquired by a grant of the Board of Directors of the Company at their annual meeting on June 14, 2024. Fully vests on the earlier of (A) the date of the next annual meeting of the Company stockholders following the grant date or (B) on the first anniversary of the date of grant. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 20:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantEmployee Stock Option (right to buy) · Derivative | 11,345 | $0.00 Strike: $59.08 | $0.00 |
DisclosureSEC source: 0000886163-23-000069 · edgardoc.xml · derivative · entry 2 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,345 Underlying: Common Stock · 11,345 shares Expires 2033-09-22 F2 · derivative.exercise_date: Grant of Stock Options that will vest and become exercisable in three substantially equal annual installments on September 22, 2024; September 22, 2025; and September 22, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| September 22, 2023 Filed Sep 26, 2023 20:41 UTC | LIGAND PHARMACEUTICALS INC LGND · Entity 3825 | GrantCommon Stock | 2,285 | $0.00 | $0.00 |
DisclosureSEC source: 0000886163-23-000069 · edgardoc.xml · nonDerivative · entry 1 Zimmermann Martine · CIK 0001994049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,285 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest over three years, in three substantially equal annual installments on September 22, 2024; September 22, 2025; and September 22, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.